Pliant Therapeutics to Participate in Upcoming Investor Events

Rhea-AI Summary

Pliant Therapeutics, Inc. (PLRX) announced their participation in investor events, including the Oppenheimer 34th Annual Healthcare Life Sciences Conference and the Wells Fargo 2024 West Coast Biotech Tour. The company's President and CEO, Bernard Coulie, M.D., Ph.D., and Chief Medical Officer, Éric Lefebvre, M.D., will be participating in a fireside chat on February 13, 2024, at 12:00 p.m. Eastern Time. Members of Pliant's senior management will also meet with investors on February 28, 2024, as part of an invitation-only event hosted by Wells Fargo.

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced participation in the following February investor events.

• Oppenheimer 34th Annual Healthcare Life Sciences Conference Bernard Coulie, M.D., Ph.D., Pliant’s President and Chief Executive Officer and Éric Lefebvre, M.D., Pliant’s Chief Medical Officer, will participate in a fireside chat on Tuesday, February 13, 2024, at 12:00 p.m. Eastern Time.
• Wells Fargo 2024 West Coast Biotech Tour Members of Pliant’s senior management will meet with investors on Wednesday, February 28, 2024, as part of an invitation-only event hosted by Wells Fargo.

Interested parties may access the live webcast of the Oppenheimer fireside chat by visiting the Investor Relations’ Events & Presentation page of Pliant’s website. The webcast replay will be archived on the Pliant website for 30 days following the conclusion of the event.

About Pliant Therapeutics, Inc.

Pliant Therapeutics is a clinical-stage biopharmaceutical company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases. Pliant's lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. Bexotegrast has received Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in IPF and PSC and Orphan Drug Designation from the European Medicines Agency in IPF and PSC. Pliant has initiated BEACON-IPF, a Phase 2b trial of bexotegrast in IPF. Pliant has also developed PLN-1474, a small molecule, selective inhibitor of αvß1 integrin for the treatment of nonalcoholic steatohepatitis, or NASH with liver fibrosis. Pliant has initiated a Phase 1 study for its third clinical program, PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being developed for the treatment of solid tumors. In addition to clinical-stage programs, Pliant currently has a preclinical program targeting muscular dystrophies. For additional information, please visit: www.PliantRx.com. Follow us on social media X, LinkedIn, Facebook and YouTube.

Investor and Media Contact:

Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
ir@pliantrx.com

When is the Oppenheimer 34th Annual Healthcare Life Sciences Conference?

The Oppenheimer 34th Annual Healthcare Life Sciences Conference is on Tuesday, February 13, 2024.

Who will be participating in the fireside chat at the Oppenheimer conference?

Pliant's President and CEO, Bernard Coulie, M.D., Ph.D., and Chief Medical Officer, Éric Lefebvre, M.D., will be participating in the fireside chat.

When will Pliant's senior management meet with investors at the Wells Fargo event?

Pliant's senior management will meet with investors on Wednesday, February 28, 2024, as part of an invitation-only event hosted by Wells Fargo.

Where can interested parties access the live webcast of the Oppenheimer fireside chat?

Interested parties can access the live webcast on the Investor Relations’ Events & Presentation page of Pliant’s website.